LifeSci Biotechnology Products Index ("LSCIBP") is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering or product candidate that has received U.S. Food and Drug Administration approval. The inception date for LSCIBP was November 3, 2014.
